Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Understanding the role of USP11 in TGFbeta signaling
FY 2009-10
Summary
Characteristic features of cancerous cells are their abilities to divide (proliferate) and move (migrate and/or invade). Transforming growth factor beta (TGFbeta) is a secreted protein that plays important roles in both cell division and cell migration, and therefore has received considerable attention by cancer researchers. TGFbeta plays dual roles in cancer. In early stages, it acts to prevent proliferation and migration, but paradoxically in more advanced cancers it promotes migration (metastasis) in established tumors. Anti-proliferative effects of TGFbeta are partially mediated via the tumor suppressor p53, though how remains incompletely understood. p53 expression or function is compromised in most cancers. Excessive p53 degradation in cancer cells by means of ubiquitination (a degradation signal) is one way that p53 function may be compromised. Ubiquitin-specific peptidase 11 (USP11) has been proposed to stabilize p53, possibly by removing ubiquitin. I have recently demonstrated that USP11 interacts with SMAD2 - a key mediator of TGFbeta signaling. SMAD2 interacts with p53 to regulate gene transcription, therefore, I hypothesize that SMAD2 acts as a scaffold to recruit USP11 to p53 stabilizing it against degradation. Loss of p53 stabilization by USP11 due to deficient TGFbeta/SMAD2 signaling may be a potential mechanism contributing to cancer progression and metastasis. Therefore, elucidating the role of USP11 in TGFbeta signaling will be important to understand its role in carcinogenesis and may provide new therapeutic targets for cancer treatment.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
200336
Name
Ouspenskaia Tamara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Understanding the role of USP11 in TGFbeta signaling
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cell Signaling; Microarray; P53; Smad; Tap Tagging; Transcription Regulation; Transforming Growth Factor Beta; Ubiquitin Peptidase; Usp11
Abstract
Characteristic features of cancerous cells are their abilities to divide (proliferate) and move (migrate and/or invade). Transforming growth factor beta (TGFbeta) is a secreted protein that plays important roles in both cell division and cell migration, and therefore has received considerable attention by cancer researchers. TGFbeta plays dual roles in cancer. In early stages, it acts to prevent proliferation and migration, but paradoxically in more advanced cancers it promotes migration (metastasis) in established tumors. Anti-proliferative effects of TGFbeta are partially mediated via the tumor suppressor p53, though how remains incompletely understood. p53 expression or function is compromised in most cancers. Excessive p53 degradation in cancer cells by means of ubiquitination (a degradation signal) is one way that p53 function may be compromised. Ubiquitin-specific peptidase 11 (USP11) has been proposed to stabilize p53, possibly by removing ubiquitin. I have recently demonstrated that USP11 interacts with SMAD2 - a key mediator of TGFbeta signaling. SMAD2 interacts with p53 to regulate gene transcription, therefore, I hypothesize that SMAD2 acts as a scaffold to recruit USP11 to p53 stabilizing it against degradation. Loss of p53 stabilization by USP11 due to deficient TGFbeta/SMAD2 signaling may be a potential mechanism contributing to cancer progression and metastasis. Therefore, elucidating the role of USP11 in TGFbeta signaling will be important to understand its role in carcinogenesis and may provide new therapeutic targets for cancer treatment.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ouspenskaia, Tamara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~